Celgene, Jounce in $2.6-bn immuno-oncology deal
Celgene and Jounce Therapeutics have linked in a global strategic collaboration striving to develop and commercialise immuno-oncology treatments.
Read More
Tag: JTX-2011
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
